Stoke Therapeutics, Inc. (STOK) Retained Earnings (Accumulated Deficit) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Stoke Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2018 to 2024.
  • Stoke Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was -$428 M, a 33.9% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 -$428 M -$109 M -33.9% Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$402 M -$105 M -35.2% Dec 31, 2023 10-Q 2024-05-06
Q3 2023 -$375 M -$103 M -38.1% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$350 M -$105 M -42.8% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 -$320 M -$99 M -44.8% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 -$297 M -$101 M -51.5% Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$271 M -$99.9 M -58.2% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$245 M -$96.3 M -64.6% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 -$221 M -$93.7 M -73.7% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 -$196 M -$85.8 M -77.8% Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$172 M -$75.9 M -79.3% Sep 30, 2021 10-Q 2021-11-08
Q2 2021 -$149 M -$67 M -81.7% Jun 30, 2021 10-Q 2021-08-10
Q1 2021 -$127 M -$58 M -84% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 -$110 M -$52.2 M -90% Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$95.7 M -$47.8 M -99.9% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 -$82 M -$42.8 M -109% Jun 30, 2020 10-Q 2020-08-10
Q1 2020 -$69.1 M Mar 31, 2020 10-Q 2020-05-15
Q4 2019 -$58 M -$32.3 M -126% Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$47.9 M Sep 30, 2019 10-Q 2019-11-12
Q2 2019 -$39.3 M Jun 30, 2019 10-Q 2019-08-14
Q4 2018 -$25.7 M Dec 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.